Roche extends tender offer for Foundation Medicine, Inc.
2 March 2015 | By Roche
Roche announced that it has extended the expiration of its tender offer to purchase up to 15,604,288 of the outstanding common shares of Foundation Medicine, Inc...
List view / Grid view
News
CHMP recommends JINARC® (tolvaptan) for approval in EU for treatment of autosomal dominant polycystic kidney disease
2 March 2015 | By Otsuka Pharmaceutical Co. Ltd
Otsuka Pharmaceutical Co., Ltd. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended JINARC® (tolvaptan) for approval...
Amgen receives positive CHMP opinion for use of Vectibix® (panitumumab) as first-line treatment for advanced colorectal cancer
2 March 2015 | By Amgen
Amgen announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion to extend the marketing authorization for Vectibix® (panitumumab) to include combination with FOLFIRI (an irinotecan-based chemotherapy) as first-line treatment in adult patients with wild-type RAS metastatic colorectal cancer (mCRC)...
Gilead announces SVR12 rates from Phase 3 study evaluating Harvoni® for the treatment of chronic hepatitis C in patients co-infected with HIV
27 February 2015 | By Gilead Sciences
96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...
Gilead announces Phase 3 results for investigational once-daily single tablet HIV regimen containing tenofovir alafenamide (TAF)
27 February 2015 | By Gilead Sciences
First TAF-based regimen found to be non-inferior with improved renal and bone parameters compared to stribild®...
Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib
27 February 2015 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia® (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib...
Moberg Pharma AB (Publ) year-end report 2014
27 February 2015 | By Moberg Pharma
Successful fourth quarter and the first profitable full year...
UCB Full Year Report 2014: Core medicines grow by 24% while next wave of new potential solutions for patients advances
27 February 2015 | By UCB
"UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient solutions: brivaracetam, epratuzumab and romosozumab..."
ALLY trial demonstrates 97% hepatitis C cure rates among patients coinfected with HIV after ribavirin-free investigational 12-week regimen of daclatasvir and sofosbuvir
27 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) coinfected with HIV – a patient population that historically has been challenging to treat in large part due…
Japanese pharmaceutical market value edging towards $80 billion by 2020, says GlobalData
27 February 2015 | By GlobalData
Japan’s pharmaceutical market value is set to grow at a tepid Compound Annual Growth Rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the healthcare burden of the country’s aging population, according to research and consulting firm GlobalData...
Johnson & Johnson tops IDEA Pharma’s Productive Innovation Index for the third consecutive year
Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most effective at developing and commercialising new medicines – bringing innovations to market successfully.
Fungal disease deaths – just “$30 a person” for major reductions in AIDS globally
26 February 2015 | By GAFFI
Early detection and treatment of fungal meningitis and pneumonia can save hundreds of thousands of lives, for a cost of 'only $30' per HIV patient, the world's first stakeholder meeting on fungal diseases hosted by GAFFI (Global Action Fund for Fungal Infections) and held in Seattle, USA has concluded...
48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation
26 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients...
Global atrial fibrillation treatment market to peak at $9.4 Billion in 2020, says GlobalData
26 February 2015 | By GlobalData
The global market for atrial fibrillation (AF) treatment will more than double in value from $4.6 billion in 2013 to peak sales of $9.4 billion in 2020, before declining to $5.7 billion by 2023 as new oral anticoagulants (NOACs) become genericized, according to research and consulting firm GlobalData...
Sanofi receives FDA approval of once-daily basal insulin Toujeo®
26 February 2015 | By Sanofi
The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...
